Taher Elmozugi

Dr. Taher Elmozugi

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2025 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
MKMuataz Kashbour
Muataz Kashbour
AAAbubaker Abdelmalik
Abubaker Abdelmalik
MYMazen Negmeldin Aly Yassin
Mazen Negmeldin Aly Yassin
MAMohamed Abed
Mohamed Abed
EAEbtesam Aldieb
Ebtesam Aldieb
FAFakhruddin Almuzghi
Fakhruddin Almuzghi
To systematically and statistically evaluate evidence from randomized controlled trials (RCTs) investigating the efficacy and safety of somatic stem cells in achieving glycemic control in type 1 and 2 diabetic patients. Bibliographic databases including PubMed, Scopus, Web of Science, and Cochrane Library were searched from the time of their establishment till January 2024. Obtained records were meticulously screened by title, abstract, and full text to include only RCTs seeking mesenchymal stem cells (MSCs) treatment for type 1 diabetes mellitus (T1DM) and 2 diabetes mellitus (T2DM). Included studies underwent quality assessment using the Cochrane risk of bias 2 tool (ROB2). Thirteen studies were deemed eligible for meta-analysis, encompassing 507 patients (T1DM = 199, T2DM = 308). To measure treatment efficacy, the present meta-analysis was conducted on outcomes reported after 12 months following treatment. MSCs therapy group was associated with a significantly reduced glycosylated hemoglobin (HbA1c) compared to the control group, MD = -0.72; 95% CI: [-1.11 to -0.33], P = 0.0003, I2 = 56%. Daily insulin requirement was lower in the MSCs group versus placebo, MD = -14.50; 95% CI: [-19.45 to -9.55], P < 0.00001, I2 = 0%. Pooled fasting C-peptide levels were significantly higher in the MSCs group compared to placebo, MD = 0.24; 95% CI: [0.05 to 0.43], P = 0.01, I2 = 93%. Postprandial blood glucose (PPBG) was observed to be significantly lower in the MSCs arm in contrast to placebo, MD = -11.32; 95% CI: [-16.46 to -6.17], P < 0.0001, I2 = 17%. However, pooled analysis of fasting blood glucose (FBG) was not significantly different between both groups, MD = -6.22; 95% CI: [-24.23 to 11.79], P = 0.50, I2 = 81% at the end of the 12-month follow-up. Mesenchymal stem cell-derived therapy is an efficacious glycemia-lowering modality agent compared to conventional therapy in T1DM and T2DM patients. Albeit more sizeable and longer RCTs are warranted to further support and standardize their clinical use. The online version contains supplementary material available at 10.1186/s13098-025-01619-6.

11 August 2024 in Pediatric Research
Verified
Journal Article
Closed access
PDF file
AEAnas Elgenidy
Anas Elgenidy
EGEman F. Gad
Eman F. Gad
ISIslam Shabaan
Islam Shabaan
HAHasnaa Abdelrhem
Hasnaa Abdelrhem
PWPaula Gamal Wassef
Paula Gamal Wassef
Khaled SaadKhaled Saad
Khaled Saad

21 December 2024 in Naunyn-Schmiedeberg's Archives of Pharmacology
Verified
Journal Article
Closed access
PDF file
AEAnas Elgenidy
Anas Elgenidy
HIHoda Atef Abdelsattar Ibrahim
Hoda Atef Abdelsattar Ibrahim
Taher ElmozugiTaher Elmozugi
Taher Elmozugi
NANagham N. Abdelhalim
Nagham N. Abdelhalim
MAMohammed A. Al-Kurdi
Mohammed A. Al-Kurdi
Khaled SaadKhaled Saad
Khaled Saad

5 March 2026 in Cardiovascular Innovations and Applications
Verified
Journal Article
Open access
PDF file
Taher ElmozugiTaher Elmozugi
Taher Elmozugi
MSMotasam Belah Al Swayah
Motasam Belah Al Swayah
AEAbdulmoez Fauzi Elmesherghi
Abdulmoez Fauzi Elmesherghi
OAOmar M. Ali
Omar M. Ali
MSMohamed El Sayed
Mohamed El Sayed
AAAbdullah K. Alassiri
Abdullah K. Alassiri
Tricuspid regurgitation (TR) is common and associated with substantial morbidity and mortality. Although optimized medical therapy (OMT) can alleviate symptoms, it may be insufficient in severe cases, and surgical interventions carry considerable procedural risk, limiting their use; consequently, tricuspid transcatheter valve interventions (TTVIs) have emerged as a less invasive alternative. We conducted a systematic search of PubMed, Scopus, and Web of Science to identify randomized clinical trials and observational studies comparing TTVI plus OMT versus OMT alone. The primary outcome was all-cause mortality, and secondary outcomes included heart failure (HF) hospitalization and a combined outcome of all-cause mortality and HF hospitalization. Eight studies (five observational and three randomized trials) comprising 4836 patients were included. Compared with OMT alone, TTVI plus OMT was associated with a significant reduction in all-cause mortality (HR = 0.59, 95% CI: 0.44–0.78, P < 0.001) and HF hospitalization (HR = 0.69, 95% CI: 0.49–0.96, P = 0.03), and it significantly reduced the combined outcome (HR = 0.59, 95% CI: 0.47–0.74, P < 0.001). However, subgroup analysis showed that the mortality benefit was driven primarily by observational studies (HR = 0.48, 95% CI: 0.37–0.61), whereas randomized trials demonstrated no significant difference (HR = 0.88, 95% CI: 0.75–1.03). Overall, TTVI combined with OMT may be associated with lower mortality and HF hospitalization compared with OMT alone, although the apparent benefit is largely derived from non-randomized evidence.

4 November 2025 in Circulation
Verified
Journal Article
Closed access
ZOZina Otmani
Zina Otmani
Taher ElmozugiTaher Elmozugi
Taher Elmozugi
AEAbdulmoez Fauzi Elmesherghi
Abdulmoez Fauzi Elmesherghi
OAOmar M. Ali
Omar M. Ali
MSMohamed El Sayed
Mohamed El Sayed
MSMotasam Belah Al Swayah
Motasam Belah Al Swayah
Background: Tricuspid regurgitation (TR) disease has a high incidence and prevalence. and while optimized medical therapy (OMT) helps with symptoms, it may be inadequate in severe cases. Surgical options carry significant risks. Hence, less invasive Tricuspid Transcatheter Valve Interventions (TTVI) become suitable for TR treatment. In our meta analysis , we aimed to compare TTVI combined with OMT versus OMT alone. Methods: A systematic search was performed for three databases (PubMed, Scopus, and Web of Science) to identify any relevant studies comparing TTVI plus OMT versus OMT alone. The primary outcome was all-cause mortality. The Secondary outcome was heart failure (HF) hospitalization, and the combined outcome of all-cause mortality and heart failure hospitalization. We used hazard ratio (HR) for dichotomous outcomes. Results: Eight studies, five observational and three randomized controlled trilas (RCTs), with a total number of patients 4791 were included in our study. In the analysis, all-cause mortality was significantly lower with TTVI combined with OMT (HR 0.59, 95% CI: 0.44-0.78, P = 0.0002) over OMT alone. Furthermore, regarding HF hospitalization, the analysis favoured TTVI with OMT over OMT alone (HR 0.69, 95% CI: 0.49-0.96, P = 0.03). Conclusion: This study demonstrates that treatment with TTVI combined with OMT significantly reduces all-cause mortality and HF hospitalization compared to OMT alone.

14 January 2026 in Acta Diabetologica
Verified
Journal Article
Closed access
PDF file
Taher ElmozugiTaher Elmozugi
Taher Elmozugi
HKHamza Khelifa
Hamza Khelifa
AMAhmed Badr Mahmoud
Ahmed Badr Mahmoud
MHMohamed K. Harfoush
Mohamed K. Harfoush
MSMazen Momtaz Shehata
Mazen Momtaz Shehata
MSMotasam Belah Al Swayah
Motasam Belah Al Swayah